

## Fanny CHARBONNIER-BEAUPEL

PharmD, PhD

Praticien hospitalier

Pharmacie à usage intérieur, REQPHARM,

Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix

47/83 boulevard de l'Hôpital 75013 PARIS

☎ +33 1 42 16 20 27 📠 +33 1 42 16 09 44 ✉ [fanny.charbonnier@aphp.fr](mailto:fanny.charbonnier@aphp.fr)



## EDUCATION

---

2017	<b>Degree in advanced therapy medicinal products management (DU Médicaments de thérapie innovante)</b> R. Descartes Univ. (Paris V University)
2013	<b>PhD in Neurosciences</b> UPMC (Paris VI University)
2010	<b>PharmD</b> R. Descartes Univ. (Paris V University)
2007	<b>Degree in statistical methodology and clinical practice (DIU CESAM)</b> UPMC (Paris VI University)
2006	<b>Master degree in clinical pharmacology</b> UPMC (Paris VI University)

## CURRENT POSITION

---

Pitié-Salpêtrière hospital - department of Pharmacy - lead pharmacist for clinical trials.

## EXPERIENCE, SKILLS

---

- **Clinical trials and advanced therapy medicinal products:** Management, dispensing, preparation. GCP knowledge (date of last GCP training: Sept 17, 2018). Pharmaceutical support to investigators for the development of institutional research projects.
- **Research:** Pharmacogenomics; biomarker research in Neurology

## PUBLICATIONS

---

- **Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.** Mov Disord. 2018 Nov 16.
- **Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.** Cell Tissue Res. 2018 Mar 7.
- **A randomized, controlled, double-blind, crossover trial of triheptanoin in alternating hemiplegia of childhood.** Orphanet J Rare Dis., 2017.
- **Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial.** PLoS One, 2016.
- **A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia.** Neurology, 2016.
- **Gene Expression Analyses Identify Narp Contribution in the Development of l-DOPA-Induced Dyskinesia.** J Neurosci, 2015.
- **Mitogen- and stress-activated protein kinase 1 is required for specific signaling responses in dopamine-denervated mouse striatum, but is not necessary for l-DOPA-induced dyskinesia.** Neurosci Lett, 2014.
- **Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study.** Ther Drug Monit, 2014.
- **The autophagy/lysosome pathway is impaired in SCA7 patients and SCA7 knock-in mice.** Acta Neuropathol, 2014.
- **Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease.** Parkinsonism Relat Disord, 2013.
- **The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.** J Neurol Neurosurg Psychiatry, 2013.
- **RAD51 Haploinsufficiency Causes Congenital Mirror Movements in Humans.** Am J Hum Genet, 2012.
- **The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.** Ann Neurol, 2011.